MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- PFIZER LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Pfizer Quarterly Results (PFIZ)
Here are the latest quarterly results of Pfizer. For more details, see the Pfizer financial fact sheet and Pfizer share price and chart. For a sector overview, read our pharmaceuticals sector report.
Pfizer Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
3
Dec-19 |
3
Mar-20 |
3
Jun-20 |
3
Sep-20 |
3
Dec-20 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 5,357 | 5,444 | 5,671 | 5,382 | 5,020 | 5,149 | 5,954 | 5,935 | |
| Other income | Rs m | 355 | 358 | 448 | 582 | 452 | 172 | 122 | 146 | |
| Turnover | Rs m | 5,711 | 5,802 | 6,118 | 5,964 | 5,472 | 5,321 | 6,076 | 6,081 | |
| Expenses | Rs m | 3,847 | 3,782 | 4,029 | 4,047 | 3,933 | 3,286 | 3,921 | 3,967 | |
| Gross profit | Rs m | 1,510 | 1,662 | 1,642 | 1,334 | 1,087 | 1,863 | 2,033 | 1,968 | |
| Depreciation | Rs m | 176 | 250 | 251 | 247 | 284 | 271 | 277 | 272 | |
| Interest | Rs m | 6 | 22 | 26 | 25 | 36 | 30 | 47 | 39 | |
| Profit before tax | Rs m | 1,682 | 1,749 | 1,812 | 1,645 | 1,219 | 1,733 | 1,830 | 1,803 | |
| Tax | Rs m | 588 | 621 | 269 | 254 | 189 | 489 | 517 | 390 | |
| Profit after tax | Rs m | 1,095 | 1,128 | 1,543 | 1,391 | 1,030 | 1,245 | 1,314 | 1,412 | |
| Gross profit margin | % | 28.2 | 30.5 | 29.0 | 24.8 | 21.7 | 36.2 | 34.1 | 33.2 | |
| Effective tax rate | % | 34.9 | 35.5 | 14.9 | 15.5 | 15.5 | 28.2 | 28.2 | 21.6 | |
| Net profit margin | % | 20.4 | 20.7 | 27.2 | 25.8 | 20.5 | 24.2 | 22.1 | 23.8 | |
| Diluted EPS | Rs | 23.9 | 24.7 | 33.7 | 30.4 | 22.5 | 27.2 | 28.7 | 30.9 | |
| Diluted EPS (TTM) | Rs | 93.8 | 98.4 | 111.1 | 112.7 | 111.3 | 113.8 | 108.8 | 109.3 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Pfizer 3QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: VENUS REMEDIES SUVEN LIFE SCIENCES NEULAND LABS ALEMBIC SUN PHARMA
Compare PFIZER With: VENUS REMEDIES SUVEN LIFE SCIENCES NEULAND LABS ALEMBIC SUN PHARMA
Compare PFIZER With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Jumps 500 Points; Dow Futures Down by 31 Points(12:30 pm)
Share markets in India are presently trading on a strong note. The BSE Sensex is trading up by 598 points, up 1.2% at 49,331 levels.
Views on news
PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.
PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)
Nov 4, 2020 | Updated on Nov 4, 2020For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)
May 14, 2021The company's board recommended a final dividend of Rs 25 for financial year 2020-21.
What's Behind the Rally in Pharma Stocks? (Views On News)
May 11, 2021The second wave of Covid has given a new lease of life to pharma stocks.
Why Did Alembic Pharma Shares Fall Today? (Views On News)
May 5, 2021Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.
More Views on NewsMost Popular
Is Intraday Trading For You? (Fast Profits Daily)
May 13, 2021Do you think you have what it takes to be an intraday trader? Find out in this video.
My Secret to Find Breakthrough Stocks (Fast Profits Daily)
May 7, 2021I've used this trading technique for many years with great success. I'm sharing it with you today.
Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)
May 6, 2021Why are markets discounting the economic impact of Covid?
The Key to Profit from India's EV Revolution (Profit Hunter)
May 7, 2021Stocks you must consider investing in before buying your first electric vehicle.
MoreOUR TOP 5 IDEAS
- Revealing at 5pm Today: The Great Indian Wealth Project
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
PFIZER SHARE PRICE
May 17, 2021 02:24 PM
TRACK PFIZER
- Track your investment in PFIZER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PFIZER
PFIZER - PIRAMAL ENTERPRISES COMPARISON
COMPARE PFIZER WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.